Latest News From Lumira Ventures

UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

admin Engage Therapeutics, Main Page, Portfolio News

– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …

Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020

admin Forbius (Formation Biologics), Portfolio News

Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …